Statin therapy for ASCVD prevention: Difference between revisions

Revision as of 21:16, 27 October 2016

The following is a treatment algorithm proposed by the AHA/ACC guidelines committee:^[1] Initial evaluation Prior to statin initiation include:

Fasting lipid panel
- Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level !220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a secondary etiology. If nonfasting triglycerides are !500 mg/dL, a fasting lipid panel is required.
ALT
CK
Consider evaluation for other secondary causes

@@ Line 6: / Line 6: @@
 The following is a treatment algorithm proposed by the AHA/ACC guidelines committee:<ref name="pmid24222016">{{cite journal| author=Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al.| title=2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= 129 | issue= 25 Suppl 2 | pages= S1-S45 | pmid=24222016 | doi=10.1161/01.cir.0000437738.63853.7a | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24222016  }} </ref>
 [[File:ACCAHA cholesterol treatment algorithm.jpg|900px]]
+Initial evaluation Prior to statin initiation include:
+*Fasting lipid panel
+**Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level !220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a secondary etiology. If nonfasting triglycerides are !500 mg/dL, a fasting lipid panel is required.
+*ALT
+*CK
+*Consider evaluation for other secondary causes
 ==References==